How big is Aligos Therapeutics, Inc.?

As of Jun 18, Aligos Therapeutics, Inc. has a market capitalization of 46.04 million, with net sales of 3.27 million and a net profit of -53.26 million over the last four quarters. The company's shareholder's funds are -28.97 million, and total assets are 71.85 million.

Market Cap: <BR>As of Jun 18, Aligos Therapeutics, Inc. has a market capitalization of 46.04 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest four quarters, Aligos Therapeutics reported net sales of 3.27 million and a net profit of -53.26 million.<BR><BR>Balance Sheet Snapshot: <BR>As of Dec 24, the company's shareholder's funds amounted to -28.97 million, while total assets were reported at 71.85 million.

What does Aligos Therapeutics, Inc. do?

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for viral and liver diseases. As of March 2025, it has a market cap of $46.04 million and reported a net profit of $43 million, with no net sales.

Overview:<BR>Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for viral and liver diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 43 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 46.04 Million (Micro Cap)<BR><BR>Key Metrics:<BR>Debt Equity: -1.15 <BR>Return on Equity: -58.88% <BR>Price to Book: 0.40 <BR><BR>Contact Details:<BR>Address: One Corporate Dr., 2nd Floor, SOUTH SAN FRANCISCO CA: 94080 <BR>Tel: 1 302 6587581 <BR>Fax: 1 302 6555049 <BR>Website: https://www.aligos.com/

Should I buy, sell or hold Aligos Therapeutics, Inc.?

Is Aligos Therapeutics, Inc. overvalued or undervalued?

As of August 5, 2021, Aligos Therapeutics, Inc. is considered risky and overvalued due to its poor financial metrics and a year-to-date return of -74.92%, significantly underperforming the S&P 500's 12.22%.

As of 5 August 2021, the valuation grade for Aligos Therapeutics, Inc. moved from does not qualify to risky, indicating increased concerns about its financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 0.38 and an EV to EBITDA ratio of 1.07, which suggests that the market may be pricing in excessive optimism despite the company's losses. In comparison, peers like Checkpoint Therapeutics, Inc. and CASI Pharmaceuticals, Inc. have significantly worse valuation ratios, with EV to EBITDA ratios of -5.9896 and -1.1923, respectively, highlighting that Aligos is not the worst performer in its group despite its challenges.<BR><BR>The stock has underperformed against the S&P 500, with a year-to-date return of -74.92% compared to the index's 12.22%. This stark contrast reinforces the notion that Aligos Therapeutics is currently overvalued, as the market sentiment does not align with the company's financial performance and outlook.

Is Aligos Therapeutics, Inc. technically bullish or bearish?

As of September 2, 2025, Aligos Therapeutics, Inc. shows a mildly bearish technical trend despite some positive momentum indicators, with a year-to-date return of -74.92% compared to the S&P 500's 12.22%.

As of 2 September 2025, the technical trend for Aligos Therapeutics, Inc. has changed from mildly bullish to mildly bearish. Currently, the weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are mildly bearish, suggesting short-term weakness. The Bollinger Bands show a mildly bullish stance on the weekly chart but are bearish on the monthly chart, indicating mixed signals. The KST is bullish weekly but bearish monthly, and the OBV is mildly bearish on the weekly timeframe.<BR><BR>In terms of performance, Aligos has significantly underperformed compared to the S&P 500, with a year-to-date return of -74.92% versus the S&P's 12.22%, and a one-year return of -29.45% compared to the S&P's 17.14%. Overall, the technical stance is mildly bearish, reflecting short-term weakness despite some longer-term bullish indicators.